This product is a Human antibody that recognizes IAV HA. This antibody recognizes a new site of vulnerability on the hemagglutinin (HA) head domain and that reacts with most influenza A viruses. Although it does not neutralize influenza, this Ab exhibits some unique properties in that it rapidly disrupts HA trimers and inhibits the cell-to-cell spread of virus.
Figure 1 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in SDS-PAGE
SDS-PAGE analysis of PABJ-0204 in non-reduced and reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively
Figure 2 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in SEC-HPLC
The purity of PABJ-0204 was greater than 95% as determined by SEC-HPLC.
Figure 3 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA
ELISA analysis of PABJ-0204 was performed by coating with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).
Antigen: 2 μg/ml, 100 μL/well
The secondary antibody: HRP-Anti-Human IgG (H+L)
Figure 4 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA
ELISA analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 5 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA
ELISA analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 6 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA
ELISA analysis of PABJ-0204 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 7 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in ELISA
ELISA analysis of PABJ-0204 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with PABJ-0204. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 8 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB
Western blot analysis of PABJ-0204 was performed with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).
PABJ-0204 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane1: Reducing antigen (0.1 μg)
Lane2: Reducing antigen (0.3 μg)
Lane3: Reducing antigen (0.6 μg)
Figure 9 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB
Western blot analysis of PABJ-0204 was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 10 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB
Western blot analysis of PABJ-0204 was performed with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 11 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB
Western blot analysis of PABJ-0204 was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 12 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in WB
Western blot analysis of PABJ-0204 was performed with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABJ-0204 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 13 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB
Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H1N1 (A/Brevig Mission/1/1918) Hemagglutinin Protein (HA1 Subunit) (His Tag).
PABJ-0204 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Figure 14 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB
Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).
PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 15 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB
Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).
PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 16 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB
Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).
PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 17 Human Anti-IAV HA Recombinant Antibody (PABJ-0204) in DB
Dot Blot analysis of PABJ-0204 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).
PABJ-0204 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-078 | Recombinant Anti-IAV HA VHH Single Domain Antibody | FC, CA, IP, FuncS | Llama VHH |
HPAB-0344CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0344CQ) | ELISA, Neut | Llama VHH |
HPAB-0345CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0345CQ) | ELISA, Neut | Llama VHH |
There are currently no Customer reviews or questions for PABJ-0204. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABJ-0204, RRID: AB_3111617)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.